CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute and to Develop Novel CAR-T Technology CARsgen Therapeutics provided a business and clinical update on its immunotherapy programs. CARsgen and Shanghai Cancer Institute entered into a five year research and development agreement for the advancement of CARsgen’s CAR-T cancer immunotherapeutics. [CARsgen Therapeutics] Press Release Aelan Cell Technologies Collaborates with the Gladstone Institutes to Conduct Comparative Study on Rejuvenated Stem Cells Aelan Cell Technologies announced they have entered into an agreement with the Gladstone Institutes to further its studies on stem cell rejuvenation. Aelan Cell Technologies will be conducting a comparative study that will involve characterization of Aelan’s stem cell product against the “gold standard,” induced pluripotent stem cells genetically reprogrammed by four factors discovered by Nobel Prize winner Dr. Shinya Yamanaka of the Gladstone Institutes. [Aelan Cell Technologies (Marketwired L.P.)] Press Release Yale Professors Awarded White House BRAIN Initiative Grant Two Yale School of Medicine professors have received a federal grant supported by President Obama’s BRAIN Initiative. In 2014, the White House announced over $300 million in new investments to support public and private efforts that would “revolutionize” understanding of the brain and brain disorders such as Alzheimer’s, schizophrenia, and autism, among others. [Yale University] Press Release Canadian Researchers Pioneer Next-Generation Therapy for Prostate Cancer A team of scientists and clinicians is developing a treatment for prostate cancer using viruses that destroy cancer cells and boost the anti-cancer immune response, yet leave normal cells unharmed. The team has received $5 million from Prostate Cancer Canada and the Movember Foundation. [McMaster University] Press Release The Leukemia & Lymphoma Society Commits $28.6 Million to New Cancer Research Funding The Leukemia & Lymphoma Society announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. [Leukemia & Lymphoma Society] Press Release Grants Support Baylor Researchers’ Work on Immunotherapy for Leukemia Two Baylor College of Medicine researchers have received Translational Research Grants from the Leukemia and Lymphoma Society for projects that use immunotherapy approaches to treat leukemia. [Baylor College of Medicine] Press Release Ergomed Increases Its Co-Development Contribution up to $12,000,000 in CEL-SCI’s Phase III Head and Neck Cancer Trial Ergomed plc announced that they have expanded their co-development agreement with increased activities to be undertaken by Ergomed. Ergomed’s contribution to the Phase III study will increase from $10 million to $12 million. The companies are undertaking the Phase III trial of CEL-SCI’s investigational immunotherapy Multikine in patients with advanced primary head and neck cancer. [Ergomed plc] Press Release Merck and DNAtrix Announce Phase II Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer Merck and DNAtrix announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase II, multi-centered study of patients with recurrent glioblastoma. [Merck & Co., Inc.] Press Release SanBio Inc. Begins Recruiting Patients to Test Regenerative Treatment for Traumatic Brain Injury SanBio Inc. announced that it has opened patient recruitment for its Phase II clinical trial study to evaluate the clinical efficacy and safety of its proprietary cell therapy following traumatic brain injury. [SanBio Inc. (Business Wire)] Press Release Protalex Announces Regulatory Approval to Initiate Phase Ib Trial of PRTX-100 to Treat Immune Thrombocytopenia in France Protalex, Inc. announced that the French National Agency for Medicines and Health Products has approved the company’s clinical trial application to begin a Phase Ib study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia. [Protalex, Inc.] Press Release SITC Celebrates U.S. Food & Drug Administration Approval of First Combination Immunotherapy for the Treatment of Cancer The Society for Immunotherapy of Cancer (SITC) applauds the U.S. Food and Drug Administration’s approval of Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of advanced melanoma. [Society for Immunotherapy of Cancer] Press Release MSK’s Lorenz Studer Named a 2015 MacArthur Fellow Memorial Sloan Kettering developmental biologist Lorenz Studer has been named a 2015 MacArthur Fellow by the John D. and Catherine T. MacArthur Foundation. [Gerstner Sloan Kettering Graduate School of Biomedical Sciences] Press Release Postdoctoral Fellow Albert Kim Receives First Hearst Fellowship for Stem Cell Research How do you turn stem cells into nephrons, the functional unit of the kidney? Albert D. Kim, a postdoctoral fellow in the laboratory of Andy McMahon, is exploring this question with support from a Hearst Fellowship, an award recognizing an exceptional junior postdoctoral fellow pursuing stem cell research at USC. [Keck School of Medicine of USC] Press Release MD Anderson’s Allison Wins American Cancer Society Medal of Honor A career-long fascination with discovering the ins and outs of T cells, our immune system’s tailor-made destroyers of infections and dysfunctional cells, has earned Jim Allison, Ph.D., the American Cancer Society’s 2015 Medal of Honor for Basic Research. [The University of Texas MD Anderson Cancer Center] Press Release |